CN109195625A - 活减毒甲病毒构建体及其方法和用途 - Google Patents

活减毒甲病毒构建体及其方法和用途 Download PDF

Info

Publication number
CN109195625A
CN109195625A CN201780032818.3A CN201780032818A CN109195625A CN 109195625 A CN109195625 A CN 109195625A CN 201780032818 A CN201780032818 A CN 201780032818A CN 109195625 A CN109195625 A CN 109195625A
Authority
CN
China
Prior art keywords
virus
ires
alphavirus
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780032818.3A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔·A·利文格德
T·D·鲍威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CN109195625A publication Critical patent/CN109195625A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201780032818.3A 2016-03-31 2017-03-28 活减毒甲病毒构建体及其方法和用途 Pending CN109195625A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
US62/316,264 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
CN109195625A true CN109195625A (zh) 2019-01-11

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032818.3A Pending CN109195625A (zh) 2016-03-31 2017-03-28 活减毒甲病毒构建体及其方法和用途

Country Status (17)

Country Link
US (1) US20190106682A1 (enExample)
EP (1) EP3436062A1 (enExample)
JP (1) JP2019509750A (enExample)
KR (1) KR20180135913A (enExample)
CN (1) CN109195625A (enExample)
AU (1) AU2017241669A1 (enExample)
BR (1) BR112018069079A2 (enExample)
CA (1) CA3019536A1 (enExample)
CO (1) CO2018010359A2 (enExample)
CR (1) CR20180457A (enExample)
DO (1) DOP2018000209A (enExample)
EC (1) ECSP18081582A (enExample)
MX (1) MX2018011839A (enExample)
PE (1) PE20190178A1 (enExample)
PH (1) PH12018502120A1 (enExample)
SG (1) SG11201808479VA (enExample)
WO (1) WO2017172698A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114561366A (zh) * 2022-03-30 2022-05-31 西南民族大学 一种山羊库布病毒分离株及其应用
CN117925540A (zh) * 2024-03-22 2024-04-26 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981909B2 (en) 2018-06-06 2024-05-14 Massachusetts Institute Of Technology Circular RNA for translation in eukaryotic cells
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技（深圳）有限公司 一种常驻点的估计方法、装置、设备和介质
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
CN102083986A (zh) * 2008-01-24 2011-06-01 德克萨斯大学系统董事会 不能在蚊子中复制的减毒重组甲病毒及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
CN102083986A (zh) * 2008-01-24 2011-06-01 德克萨斯大学系统董事会 不能在蚊子中复制的减毒重组甲病毒及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAL YOUNG KIM等: "Design of Chimeric Alphaviruses with a Programmed, Attenuated,Cell Type-Restricted Phenotype", 《JOURNAL OF VIROLOGY,》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114561366A (zh) * 2022-03-30 2022-05-31 西南民族大学 一种山羊库布病毒分离株及其应用
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
CN117925540A (zh) * 2024-03-22 2024-04-26 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用

Also Published As

Publication number Publication date
KR20180135913A (ko) 2018-12-21
EP3436062A1 (en) 2019-02-06
WO2017172698A1 (en) 2017-10-05
PE20190178A1 (es) 2019-02-01
ECSP18081582A (es) 2019-02-28
US20190106682A1 (en) 2019-04-11
DOP2018000209A (es) 2019-01-31
AU2017241669A1 (en) 2018-11-22
PH12018502120A1 (en) 2019-07-15
SG11201808479VA (en) 2018-10-30
CO2018010359A2 (es) 2018-12-14
MX2018011839A (es) 2019-05-23
BR112018069079A2 (pt) 2019-01-29
JP2019509750A (ja) 2019-04-11
CR20180457A (es) 2019-04-09
CA3019536A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CN109195625A (zh) 活减毒甲病毒构建体及其方法和用途
Weiss et al. Coronavirus pathogenesis
Chua et al. The molecular basis of mouse adaptation by human enterovirus 71
Whitton et al. Host and virus determinants of picornavirus pathogenesis and tropism
Minor The polio-eradication programme and issues of the end game
US6323024B1 (en) Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
Racaniello Poliovirus neurovirulence
WO1998039426A9 (en) Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
Zimmermann et al. Cell attachment and mouse virulence of echovirus 9 correlate with an RGD motif in the capsid protein VP1
BR112019014613A2 (pt) vacina da pólio
KR102423993B1 (ko) 저온-적응-바이러스-약독화(cava) 및 신규의 약독화 폴리오바이러스 균주
BRPI0510016B1 (pt) Vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
Kim et al. Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy
Ryman et al. Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate
Yang et al. Development and evaluation of neutralizing antibodies for cross-protection against West Nile virus and Japanese encephalitis virus
WO2012106403A2 (en) Methods and compositions for pseudoinfectious alphaviruses
HK40003300A (en) Live, attenuated alphavirus constructs and methods and uses thereof
Racaniello Poliovirus
Gao et al. Reverse mutation of the virulence-associated S2 gene does not cause an attenuated equine infectious anemia virus strain to revert to pathogenicity
Bondarenko et al. Hepatitis a virus: structure-functional features of genome, molecular diagnostics, and cultivation
Bercoff Picornaviruses at the molecular level
Shegdar Towards a novel and safe EVA71 VLP vaccine: Enhancing capsid stability with thermal selection
Sarkar et al. A strategy to develop disabled infectious single-cycle (DISC) foot and mouth disease virus by 3B3 gene deletion using the infective cDNA copy of the genome
Racaniello Poliovirus vaccines
Jupille Identification of a viral determinant of virulence in Ross River virus that modulates viral replication and fitness in disparate hosts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003300

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190111

WD01 Invention patent application deemed withdrawn after publication